Psychotic Disorders

Conditions: Schizophrenia Spectrum and Other Psychotic Disorders based on DSM-5 and ICD-11 criteria | Bipolar Type I Disorder based on ICD-11 criteria
Populations: Adults aged 18 years and above and adolescents aged 12-17 years

Details:
1. Defined by Number of Hospitalisations in the Past 12 Months
2. Defined by OHME Domains: Connectedness, Hope and Optimism, Identity, Meaning and Purpose, Empowerment
3. Defined by Health-Related Quality of Life
4. Tracked via the Patient Health Questionnaire 9-Item
5. Tracked via the Modified Colorado Symptom Index
6. Tracked via the Recovering Quality of Life - 20-Item Version
7. Tracked via the Altman Self-Rating Mania Scale in Populations with Bipolar Type I Disorder
8. Tracked via the PROMIS Short Form v1.0 - Sleep Disturbance 4a
9. Tracked via the Number of Hospitalisations
10. Tracked via the WHO Disability Assessment Schedule 2.0 - 12-Item Version
11. Tracked via the KIDSCREEN-10 Index in Adolescent Specialist Services
12. Tracked via the Patient Health Questionnaire 15-Item
13. Tracked via the Glasgow Antipsychotic Side-Effect Scale

For a complete overview of this Set, including definitions for each measure, time points for collection, and associated risk factors, visit http://www.ichom.org/portfolio/psychotic-disorders/

© 2023 ICHOM. All rights reserved. When using this set of outcomes, or quoting therefrom, in any way, we solely require that you always make a reference to ICHOM as the source so that this organization can continue its work to define more Sets of Patient-Centered Outcome Measures. Version 4.1.0 Revised: February 2023
Contributors

For more information about the process of developing a Set of Patient-Centered Outcome Measures, visit ichom.org/how-we-work/

The Sponsors

The Working Group

Project Team

Chair
Donald Addington | University of Calgary

Research Fellow
Emily McKenzie | University of Calgary

Project Managers
Lucy Maskin / Luz Sousa Fialho | ICHOM

Research Associates
Beth Jagger / Christiana Besancon / Ijeoma Nneka Emelurumonye / Shannon Quinney / Timea Gintner | ICHOM

Australia
Grant Sara | NSW Ministry of Health / University of Sydney
Tim Coombs | Illawarra Institute for Mental Health University of Wollongong

Canada
Elizabeth Anderson*

Denmark
Lone Baandrup | Mental Health Centre Copenhagen

Greece
Fokion Dimitriadis*

India
Anrnt Bakhshy | Schizophrenia Awareness Association, Pune*

Israel
David Roe | University of Haifa

Mexico
Dania Nimbe Lima Sanchez | Medicine School, Universidad Nacional Autónoma de México

Netherlands
Niels C. L. Mulder | Erasmus MC, Rotterdam

United Kingdom
Alison Brabban | Tees, Esk & Wear Valleys NHS Foundation Trust / NHS England
Anju D. Keetharuth | School of Health and Related Research, University of Sheffield
Caroline Cupitt | South London and Maudsley NHS Foundation Trust
Farhad Shokraneh | University of Nottingham
Jacqueline Sin | University of Reading
Paul McCrone | Institute for Lifecourse Development, Faculty of Education, Health and Human Sciences, University of Greenwich

United States
Christoph U. Correll | Hofstra Northwell School of Medicine / Feinstein Institute for Medical Research / The Zucker Hillside Hospital, Department of Psychiatry
Kristen Woodberry | Maine Medical Center Research Institute
Mary D. Moller | Pacific Lutheran University, Tacoma, WA

*Patient representative